Enzyme ablation of the hyperplastic prostate may be an ideal method of management of BPH. However, the unsatisfactory ablation affects in vivo contrast with successful in vitro results limiting the enthusiasm for further research. In this study, we make efforts to solve the problems in the use of enzyme ablation of BPH in vivo and to measure satisfactory effect. Material and methods: A total of 18 hybrid dogs between the ages of 7 and 11 y underwent this experiment. Eight dogs were divided into four groups according to the injection formula: enzyme solution, hot D-Hanks' plus enzyme solution, hot agarose plus enzyme solution, and hot agarose solution alone. After selecting the agarose plus enzyme solution group in the first month, the remainder 10 dogs were treated with this two-stage method. Intravenous or oral antibiotics were administered perioperatively. All operations were performed directly by way of laparotomy. The prostates were observed and harvested with surrounding tissue at 24 hrs, 7 days, 14 days, 1 month and 3-5 months after treatment. Gross and microscopic examinations were performed. Results: Only agarose plus enzyme group shows obvious cavity formation with concomitant size reduction and softening of the prostate ablation effect in the four groups. At 24 h after injection, the prostates demonstrated cavity formation containing liquefied necrotic tissue. The liquefied tissue was absorbed in 7-14 days. At 1 month, the size of most prostates decreased with a corresponding decrease in the size of the cavities. The cavities nearly disappeared within 3-5 months, and the size of prostates decreased to between 1/2 and 1/4 of the pretreatment sizes. All prostates had intact urethral mucosa and capsule. No complications directly related to enzyme ablation were identified. In the control groups there were no significant cavities or decrease in prostate size. Conclusions: This two-stage thermal and enzyme ablative method can significantly ablate prostate tissue without identifiable complications, and would be possibly applied to treating human BPH in the future.
Introduction
Symptomatic benign prostate hyperplasia (BPH) is a progressive problem as men age. The gold standard for treatment of BPH is the transurethral resection of prostate (TURP). However, TURP has measurable morbidity and upto 77% of men have comorbidities, most of which may have high risk. 1 Many minimally invasive therapies have been developed in recent decades. Most of them were based on thermoablation, such as transurethral microwave thermotherapy, transurethral needle ablation of the prostate, etc. These procedures have been demonstrated to be successful compared with TURP in short-time results. Often, the long-time results have not been as effective as TURP. 2 A novel chemoablation of BPH with absolute ethanol has been performed in recent years. The first intraprostatic ethanol injections were reported in 1999, 3, 4 Absolute ethanol can effectively ablate prostatic tissue in canines with minimal systemic absorption. The prostates demonstrated necrosis and cavity formation. Clinical results [4] [5] [6] show significant improvement in mean peak urinary flow, volume of postvoid residual urine and mean quality of life score. But, there was no significant change in prostate volume. Long-term results and larger patient cohorts are still lacking.
Enzyme ablation of BPH has not progressed since Dr Barrett's report in 1998. 7, 8 Although the author described the advantages of this method, the actual effect did not support enzyme ablation as a likely future management for symptomatic BPH.
We began this study in 2002. The experience in enzyme ablation of prostate in vitro has been reported. 9 The efficacy of enzyme ablation of the prostate in vitro had previously been published. The reasons there were such significant differences in vitro and in vivo were not resolved. Failure might relate to leakage and dilution of the enzyme into urine, periprostatic tissues or the bloodstream. These changes would temper the effect of the enzyme activity in vivo. Enzymatic inhibitors in the body may have a negative effect. To solve these questions, we evaluated a two-stage intraprostatic hot agarose solution and enzyme injection method in canine models.
Materials and methods
In all, 18 hybrid dogs, 7-11 y old, obtained from the Animal Experimental Center of Wuhan University, underwent this experiment. This protocol was approved by the Institutional Animal Care and Use Committee of Wuhan University.
Pilot study
Eight dogs were divided into four groups randomly (two/group): all operations were performed directly via laparotomy. The first group was injected with enzyme solution as previously. The second group was given hot D-Hank's solution (over 801C) at first, and the enzyme was injected when the temperature of prostate had decreased to normal. The third group received hot agarose solution instead of D-Hanks'. The fourth group received hot agarose solution alone as control. All prostate glands were examined by open laparotomy at 1 week and at 1 month and the macroscopic changes were observed.
Agarose solution
Agarose (A9311, Sigma Chemical) with gel point 36.571. 51C were lysed in D-Hanks' solution by heating to 801C and diluted to 1.5% agarose solution. The hot agarose solution was maintained in a sterile vacuum flask before use.
Enzyme solution
The enzyme solution only contained two types of enzyme: 5000 U/ml collagenase (Sigma Chemical, St Louis, MO, USA) and 1% trypsin (Sigma Chemical) lysed in a D-Hank's solution, which is simpler than the previous formula.
7.
The reason we believed it sufficient was based on in vitro results (unpublished data). The prepared solution was passed though a Detoxi-Gel column (pierce, Rockford, III, USA) for elimination of contaminating endotoxins before injection as protocol. 7 
Techniques
The remaining 10 dogs were treated with the third method, that is, using two-stage intraprostatic hot agarose solution and enzyme injection. The animals were anesthetized by intravenous administration of sodium pentobarbital. A laparotomy was performed through a low paramedian abdominal incision. The prostate was exposed by upward traction on the bladder neck. The pretreatment prostate volume was determined by direct measurement of three dimensions and was calculated by the standard formula (0.5233
. The bladder was incised and a resistance thermometer was placed in prostatic urethra to determine the temperature changes, while the hot agarose solution was being injected into the prostate using a 20-gauge needle. The injection ceased when the surface of prostate blanched. At this point, we thought the hot solution had reached the margin of the prostate. The amount injected was 2-6 ml into each lobe. During the injection process, the needle was withdrawn slowly along the long axis of the gland in order to ensure that the agarose solution diffused equally throughout the prostate. In about 50-60 min the temperature descended to normal canine body temperature and the agarose gel began to form. At this time, the same volume of enzyme with agarose solution was injected. The incision was sutured without any urinary catheter drainage.
Observation
The animals were examined daily. Evidence of postoperative urinary retention, gross hematuria, abdominal tenderness and other signs of distress such as constipation were recorded. The prostate glands of 12 dogs were observed or harvested with surrounding tissue at intervals of 24 h, 7 days, 14 days, 1 month and 3-5 months after treatment. Each prostate was checked twice. At the first post injection laparotomy, we measured the size of the prostate, evaluated the surface induration and dissected one lobe of the prostate to observe the cavity formation and then sutured it. At the second laparotomy the animals were killed. Any gross changes were recorded and cystoprostatectomy was performed including a distal stump of urethra. The prostates were fixed and embedded to examine the microscopic changes. The ultrasound inspection of cavity was performed at 24 h after the injection and weekly for 1 month, then once a month. The reason we did not use ultrasound to detect the size of prostate was that the dog's bladder often emptie when the dog was caught. In that situation, the Ablation of canine prostate C Zhang et al boundary of prostate may be indistinct and inaccurate by ultrasound.
Results
In the pilot study, only the group injected with the hot agarose plus enzyme solution group had macroscopic changes showing cavity formation and size decrease. In the other three groups, we did not see any macroscopic change. Unfortunately, we did not examine for histological changes in this group.
At the time of the hot agarose solution injection, the temperature of prostatic urethra reached about 461C instantaneously and then descended rapidly. Prostatic hyperemia often occurred immediately after direct injection of the enzyme. When injected with hot agarose solution, the prostate blanched as if it were bloodless. No hyperemia occurred in the prostate with second injection with the enzyme. The mean preoperative size of canine prostates in our experiments was 24.2 ml (range from 16.0 to 61.1 ml, n ¼ 12). No postoperation urinary retention or constipation occurred. Major complications were not encountered (gross hematuria, urinary tract infection, etc). In some older dogs, we observed voiding improved and their ability for self-care also improved.
In two dogs, a unilateral prostatotomy was performed at 24 h after injection. The prostate was observed to be slightly edematous with obvious spherical cavity formation containing liquefied necrotic tissue that flowed out of the site of enzyme injection. Ultrasound imaging of other dogs demonstrated cavity formation and liquidized tissue (Figure 1a) . The volume of the cavity was nearly equal to the volume of injected enzyme solutions. Cavitation does not seem to be the result of dilatation by the solution's volume (unpublished data). Four dogs were checked via laparotomy at 7 days postinjection and 4 dogs at 14 days. The findings were similar among these dogs. The prostates became soft and the cavities could be palpated through the surface. Unilateral prostatotomy revealed that most of the liquefied, necrotic tissue was absorbed and the inner wall of the cavities became smooth and we had found some small holes on the surface of the inner wall. The ultrasound views had shown a clear nonechoic cavity (Figure 1b) . At 1 month postinjection, eight dogs underwent laparotomy to measure the size of prostates and cavities. In most canines, both the prostate and cavity sizes were decreased. The thinnest site of prostate was 4 mm to the capsule or urethra. The largest prostate (61.1 ml) showed no size change which may be due to insufficient treatment dosage because the capacity we can inject into the prostate is limited, which may result in insufficient dosage, and we gave a second injection (4 ml agarose þ 4 ml enzyme) into the left lobe. Four dogs were examined at 3 months and two dogs with larger prostates were examined at 5 months. Half of the cavities had disappeared in dogs with small glands receiving relatively small volume injections. The remaining dogs had only a residual shallow pit. In these animals, it was difficult to find any evidence of a cavity using ultrasound. In the animal receiving a second injection into the left lobe, cavity formation and thinning of the prostate tissue was noted. The sizes of all prostates decreased to 1/2 and 1/4 of primary size (Figure 2a-c) . The mean size of prostate was 9.5 ml (range from 5.1 to 25.9 ml, n ¼ 6).
In histological studies, the treated 'remainder' prostates showed changes comparable to the results of previous studies 7, 8 . The hyperplasic stratified glandular epithelium became vacuolated with residual base structure; the stroma became acellular with short, broken and sparse fibers. The smooth muscles were discontinuous. Delineation could be seen between the ablated tissue and unaffected hyperplasic tissue (Figure 3a,b) . In some areas, we observed infiltration by lymphocytes which may have been caused by heterogeneous protein or necrosis, and this inflammation was lessening with time after treatment.
Discussion
Studies of enzyme ablation of the hyperplastic prostate are uncommon. Prior publications showed results that were less effective than the other minimally invasive therapies. Only histological changes could be seen in prostatic tissue. Since significant effects occur in vitro, one still needs to explore the reasons for such limited effects in vivo. The key problem in enzyme ablation was not the formula of the enzyme, although the collagenase Figure 1 (a) At 24 h postoperation, a 'fingerprint' cavity could be seen in the left lobe. The prostatic urethra could not be seen. (b) 14 days after treatment, a clear cavity in the left lobe without echo could be seen nearby the urethra under ultrasound, and the prostatic urethra became wide and clear.
Ablation of canine prostate C Zhang et al was basic and essential. The most important hurdle was to increase the effects and control the dispersion of enzymes within the gland. In Harmon and Barrett's study, 7, 8 we can see the dosage of enzyme had no correlation with the effect. So we assumed the small effect in vivo had two reasons: first, most of the enzyme had leaked into body via the blood stream and lymphatic channels; second, enzymatic inhibitors in the body may temper the effect of enzymatic ablation.
After our pilot study, the hot agarose and enzyme solution group was selected for further study. Although the thermoablation with hot D-Hanks' solution did achieve satisfactory hemostasis and destroyed most viable cells, it had shown no macroscopic effect on prostate. In comparing the results between the hot agarose solution and hot D-Hanks' solution, there exist positive advantages of our method and the use of hot agarose. First, the slow heat conduction of the hot agarose solution can produce enough time-heat ablation and may damage any enzymatic inhibitors produced by viable prostate cells while not damaging the surrounding tissues. Second, hot agarose solution appears to result in coagulation of blood vessels in prostate; perhaps preventing the leakage of enzyme, preventing inhibitors in the serum from entering the prostate, and, preventing hematoma formation. Third, the agarose gel point occurs at approximately 371C. The gel formation might block the prostatic ducts and prevent the leakage of enzyme, thus limiting the extension of enzymatic ablation. Fourth, the agarose gel is used for protein electrophoresis, suggesting that the injected enzyme may diffuse into gel and become extended release. Finally, the agarose gel is innocuous. The hot agarose solution control had shown the ablative effects were not the result of hot agarose solution alone. 
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Our studies showed satisfactory macroscopic ablation and resulting in significant prostate volume decrease without any capsular disruption into the surrounding tissues. We surmise that the mechanism of ablation (see Figure 4 ), may include two consecutive ablative processes. In the first 24 h, the undiffused and flowing enzyme dissolved prostatic tissue to form the cavity by local diffusion or gravity. This can explain why the cavity's volume was similar to the volume of enzyme. We call this 'rapid ablation'. And the rapid ablation did not stop then, the gravity may result in tissue ablation in dependent sites. On the other hand, as we can see during TURP, the contraction of the capsule may maintain persistent contact of tissue with the enzyme. The rapid ablation effect may not stop until a small 'channel' forms to the periprostatic tissues, possibly as a result of the ablation itself. This enzyme leak to the body may occur at 7-14 days postoperation. The enzyme diffused in agarose gel can also dissolve the tissue but the effect is gentle (unpublished data by a simulant condition in vitro), we call it 'delayed ablation'. The delayed ablation could further induce collapse of the structure of prostate, and gradually reduce the size of the prostate. But the duration of enzyme activity is still unknown and the complicated mechanisms of action should be explored.
Conclusions
In the canine model, the results of our study had showed the obvious superiority over the other minimally invasive therapies because it can result in softening of prostate and decrease in size. The dog supplemented with a second treatment suggested that the repeat therapy is possible and effective. The absence of capsule or urethra injury and that of any visible complications in our subject further support the safety. We also believe that the solutions could be injected through transurethral or transperineal approach under the ultrasound guide in the clinic trial. Another issue we should pay attention to is that the canine prostate had great differences from human prostate, especially in histology. 10 It should be considered when the technique is applied in the human BPH treatment.
